Context Therapeutics (CNTX) Live Share Price, Invest From India

Context Therapeutics Stock Performance

as on October 1, 2026 at 3:10 am IST

Day's Low
Day's High
$0.30
Day's Price Range
$0.32
$0.31
2.31%
Downside
4.20%
Upside
52 Week's Low
52 Week's High
$0.31
52-Week Price Range
$3.62
$0.31
-1.48%
Downside
1078.77%
Upside

Context Therapeutics share price movements today

Previous Close: $0.32
Open: $0.32
Volume: 514.1K
Market Cap: $30.0M
Day's Low - High: $0.30 - $0.32
52 Week Low - High: $0.31 - $3.62

Context Therapeutics Historical Returns

1 Month Return: -16.86 %
3 Month Return: -42.41 %
1 Year Return: -67.07 %
3 Year Return: -78.87 %
5 Year Return: 0 %

Context Therapeutics Stock Fundamentals & Key Indicators

Check Context Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$30.0M

EPS (TTM)

-0.4812

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.68

Industry PE ratio

-2.66

PEG Ratio

0.02

EBITDA

-45.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-82.06%

Context Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Context Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Context Therapeutics	Buy	$30.0M	NA	-0.68	0.00%	0.00%
Revolution Medicines	StrongBuy	$43.2B	643.29%	-22.77	0.00%	0.00%
Moderna	Neutral	$78.8B	-47.13%	-24.72	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$133.4B	189.75%	30.38	86.04%	0.00%
Regeneron	Buy	$81.1B	24.01%	17.96	84.86%	0.49%

Stock Returns calculator for Context Therapeutics Stock including INR - Dollar returns

The Context Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Context Therapeutics investment value today

Current value as on today

₹34,193

Returns

-₹65,807

(-65.81%)

Returns from Context Therapeutics Stock

-₹68,301 (-68.3%)

Dollar Impact

₹2,494 (+2.49%)

Analyst Recommendation on Context Therapeutics Stock

Based on 2 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 2 analysts, 50% of analysts recommend a 'BUY' rating for Context Therapeutics. Average target price of $4.25

Context Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Context Therapeutics.

What analysts predicted

92.77%UPSIDE

Target Price

$4.25

Current Price

$0.3071

Analyzed by

2 Analysts

High

Target

$4.25

Low

Context Therapeutics target price $4.25, a slight upside of 92.77% compared to current price of $0.3071. According to 2 analysts rating.

Indian Investors' Interest in Context Therapeutics Stock

Search interest for Context Therapeutics Stock has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 31, 2026 to September 30, 2026

Change:-52% versus previous 30 day period

Context Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	0	-	0	-
Operating Income	-3	-3	-18	-4	-5	-9	-10	-13	-9	-14
EBITDA	-3	-2	-17	-3	-4	-8	-9	-13	-8	-14
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-3	-2	-17	-3	-4	-8	-9	-13	-8	-14
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-3	-2	-17	-3	-4	-8	-9	-13	-8	-14
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Context Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-
Operating Income	-5	-2	-10	-15	-25	-29	-39
EBITDA	-5	-2	-10	-14	-23	-26	-36
Interest Expense	1	0	0	0	-	-	-
Depreciation	-	-	-3	0	0	0	0
Income Before Tax	-6	6	-10	-14	-23	-26	-36
Income Tax Expense	-	-	-	-	-	-	-
Net Income	-6	6	-10	-14	-23	-26	-36
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Context Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-3	-2	-17	-3	-4	-8	-9	-13	-8	-14
Operating Cash Flow	-4	-3	-1	-4	-5	-5	-6	-8	-11	-7
Investing Cash Flow	-	-	-14	-	0	-	-	-2	0	-4
Financing Cash Flow	-	94	0	14	0	-	-	-	-	-
Change in Cash	-4	91	-16	9	-5	-5	-6	-10	-11	-11

Context Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-6	6	-10	-14	-23	-26	-36
Operating Cash Flow	-2	-1	-8	-13	-21	-14	-26
Investing Cash Flow	-	-	0	0	-	-14	-2
Financing Cash Flow	1	1	58	0	-	109	0
Change in Cash	0	0	49	-14	-21	79	-28

Global Institutional Holdings in Context Therapeutics

Check out the Institutions with significant holdings in Context Therapeutics.

Funds	Holdings
Vanguard	4.33%
iShares	3.82%
VANGUARD INDEX FUNDS	3.63%
Stephen A. Schwarzman	2.66%
Franklin Strategic Series	1.52%

See all

Insights on Context Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 97.0% return, outperforming this stock by 175.9%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 687.7% return, outperforming this stock by 754.8%
NEGATIVE IMPACT
Price Dip
In the last 7 days, CNTX stock has moved down by -16.6%

About Context Therapeutics

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Organisation	Context Therapeutics
Headquarters	2001 Market Street, Philadelphia, PA, 19103, US
Industry	Biotechnology
CEO	Martin A. Lehr

Key Management of Context Therapeutics

Name	Title
Mr. Martin A. Lehr	Co-Founder, President, CEO & Director
Ms. Jennifer Minai-Azary	CFO & Treasurer
Mr. Alex C. Levit Esq., J.D.	Chief Legal Officer & Corporate Secretary
Mr. Christopher Beck M.B.A.	Senior Vice President of Operations
Mr. Jeffrey Liebman	Associate Director of Accounting
Ms. Jennifer Dashnau M.B.A., Ph.D.	Senior Vice President of Technical Operations
Dr. Karen Chagin M.D.	Chief Medical Officer

FAQs

What is Context Therapeutics share price today?

Context Therapeutics share price today is $0.31 as on September 30, 2026 at 9:40 pm IST. Context Therapeutics share today touched a day high of $0.32 and a low of $0.30.

What is the 52 week high and 52 week low for Context Therapeutics share?

Context Therapeutics share touched a 52 week high of $3.62 on March 16, 2026 and a 52 week low of $0.31 on September 29, 2026. Context Therapeutics stock price today i.e. September 30, 2026 at 9:40 pm IST is trending at $0.31,which is 91.52% down from its 52 week high and -1.46% up from its 52 week low.

What is Context Therapeutics's market capitalisation today?

Context Therapeutics market capitalisation is $0.00T as on September 30, 2026 at 9:40 pm IST.

How to invest in Context Therapeutics Stock (CNTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Context Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Context Therapeutics Stock (CNTX) from India?

Indian investors can start investing in Context Therapeutics (CNTX) shares with as little as ₹95.83000183105469 or $1 (as of September 30, 2026 at 9:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹958.30 in Context Therapeutics stock (as per the Rupee-Dollar exchange rate as on September 30, 2026 at 9:40 pm IST). Based on Context Therapeutics share’s latest price of $0.31 as on September 30, 2026 at 9:40 pm IST, you will get 32.5627 shares of Context Therapeutics. Learn more about fractional shares .